IGC Pharma IncIGC
Price$0.27Intrinsic value$0.3633% above price

Qualitative Analysis

Business overview

Business Overview

IGC Pharma, Inc. (NYSE American: IGC) is a clinical-stage biotechnology company focused on developing innovative therapies for Alzheimer's disease and other neurodegenerative conditions. The company leverages artificial intelligence (AI) alongside botanical compounds to address massive unmet medical needs in dementia care. Its lead investigational drug asset is IGC-AD1, a low-dose cannabinoid-based formulation currently in Phase 2 clinical trials (the CALMA trial) targeting agitation in dementia due to Alzheimer's. Additionally, the company is advancing TGR-63, a preclinical small-molecule candidate designed to target amyloid-beta plaques, and is developing AI-driven diagnostic and risk-assessment tools such as MINT-AD.

Research as of 20 Jun 2026

Strategic Initiatives

Growth programs, investments, and their expected impact

AI-assisted
Phase 2 CALMA Clinical TrialInnovation

Advancing the lead cannabinoid-based drug candidate, IGC-AD1, through a Phase 2 clinical trial evaluating its safety and efficacy in treating agitation associated with Alzheimer's dementia.

Expected impact: Establish proof-of-concept and safety profile to support potential regulatory pathways and commercialization partnerships.

Sign in / Sign up to read more
InvestmentR&D expenses increased 48% to $4.0 million during the nine-month transition period ended December 31, 2025, primarily driven by the expansion of this trial.
TimelineTarget enrollment of 146 patients was achieved in June 2026, with database lock and topline analysis expected in the subsequent quarters.
AI-Driven Drug Discovery and Data HarmonizationInnovation

Integrating artificial intelligence (AI) and advanced data analytics to accelerate drug discovery, optimize clinical trials, and harmonize large biomedical datasets.

Expected impact: Create future monetization opportunities by supporting global research collaborations and pharmaceutical companies working with complex neurodegenerative datasets.

Sign in / Sign up to read more
InvestmentOngoing operational and R&D allocation, including utility patent filings for the AHA AI-based data harmonization system.
TimelineContinuous development; showcased at the ADPD 2026 conference in March 2026.
Strategic National Media CampaignExpansion

Launching a 12-part national media partnership with 'New to The Street' to enhance visibility across institutional and retail investor audiences.

Expected impact: Expand investor awareness and market visibility during critical clinical trial milestones.

Sign in / Sign up to read more
InvestmentUndisclosed marketing and promotional fees.
TimelineLaunched on March 30, 2026, spanning multiple months of televised interviews, commercials, and digital amplification.

Mergers, Acquisitions & Partnerships

Recent deals and strategic collaborations

AI-assisted

Strategic Partnerships

New to The StreetMedia and Investor Relations Partnership

Designed to enhance IGC Pharma's visibility across institutional and retail investor audiences through a coordinated, multi-channel media strategy including Fox Business and Bloomberg Television.

Terms: Undisclosed

Sign in / Sign up to read more
Icahn School of Medicine at Mount SinaiClinical Trial Site Collaboration

Added as a clinical site for the Phase 2 CALMA trial to expand patient access, strengthen site quality, and support consistent execution of the trial.

Terms: Standard clinical trial site funding

Sign in / Sign up to read more
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.